ReviewTheranostics2022
Emerging microfluidics-enabled platforms for osteoarthritis management: from benchtop to bedside.
Review in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Therapeutic Targets and Signaling Mechanisms in 2D and 3D In Vitro Models of Osteoarthritis.Clinical anatomy (New York, N.Y.) · 2026Review
- Metal-on-metal hip implants: Revisiting degradation product chemistry and molecular mechanisms of ARMD.Biomaterials and biosystems · 2026Review
- Bridging the gap in OA therapeutics: Bioengineered strategies to target osteoclast-chondrocyte crosstalk.Bioengineering & translational medicine · 2026Review
- Intelligent microstructure materials for diagnosis and treatment of osteoarthritis: progress and AI-enpowered future.Bone research · 2025Review
- Impact of Fiber Orientation in Electrospun PLA Scaffolds on Fluid Dynamics in a Custom Microfluidic Device.Advanced healthcare materials · 2025Article
- Hydrodynamically generated multilayer skin spheroids enable in vitro screening of biologically active ingredients and toxicity tests.Science advances · 2025Article
- Deciphering cartilage neuro-immune interactions and innervation profile through 3D engineered osteoarthritic micropathophysiological system.Materials today. Bio · 2025Article
- Article
- Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis.Advanced healthcare materials · 2024Article
- Toward Fully Automated Personalized Orthopedic Treatments: Innovations and Interdisciplinary Gaps.Bioengineering (Basel, Switzerland) · 2024Review
- Beginning of the era of Organ-on-Chip models in osteoarthritis research.Journal of clinical orthopaedics and trauma · 2024Article
- Hierarchical Microcarriers Loaded with Peptide Dendrimer-Grafted Methotrexate for Rheumatoid Arthritis Treatment.Small science · 2024Article
- The promise of Synovial Joint-on-a-Chip in rheumatoid arthritis.Frontiers in immunology · 2024Review
- Review
- Osteochondral regenerative engineering: challenges, state-of-the-art and translational perspectives.Regenerative biomaterials · 2023Review
- Organ-on-a-chip meets artificial intelligence in drug evaluation.Theranostics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a prevalent debilitating age-related joint degenerative disease. It is a leading cause of pain and functional disability in older adults. Unfortunately, there is no cure for OA once the damage is established. Therefore, it promotes an urgent need for early detection and intervention of OA. Theranostics, combining therapy and diagnosis, emerges as a promising approach for OA management. However, OA theranostics is still in its infancy. Three fundamental needs have to be firstly fulfilled:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.